Robert Ingram
General Partner, Hatteras Venture Partners & Chairman, Viamet Pharmaceuticals

Mr. Ingram joined Hatteras Venture Partners as a General Partner in 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, Bob was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

Bob serves on the Board of Directors of Hatteras portfolio companies Viamet Pharmaceuticals, Inc. and PhaseBio Pharmaceuticals, Inc. He serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc. He is also a member of the Board of Directors of Edwards Lifesciences Corporation and Regeneron Pharmaceuticals, Inc.

In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer. He is a member of numerous other civic and professional organizations. In 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service and in 2006 he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

Bob is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.

He graduated from Eastern Illinois University with a B.S. degree in Business Administration.

Andrew von Eschenbach, M.D.

Dr. von Eschenbach was the Commissioner of the US Food and Drug Administration from 2005 to 2009. Previously, Dr. von Eschenbach was Director of the US National Cancer Institute. Prior to his government service, he was an accomplished urologist and healthcare administrator. His medical career included several leadership roles at the University of Texas M.D. Anderson Cancer Center including Chair of the Department of Urology, founding Director of the Prostate Cancer Research Program, Director of the Genitourinary Cancer Center, Distinguished Chair in Urologic Oncology, and Executive Vice President and Chief Academic Officer.

Adrian Howd, Ph.D.
Chief Investment Officer, Malin Corporation plc.

Dr. Adrian Howd is the Chief Investment Officer of Malin Corporation plc, an Irish-based global life sciences company. He has held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a Ph.D in molecular neuroscience from the University of London. Dr. Howd is a principal, director and shareholder of BPI.

Kelly Martin
CEO, Malin Corporation plc.

G. Kelly Martin is the CEO of Malin Corporation plc, an Irish-based global life sciences company. He served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards. Mr. Martin is a co-founder, director and shareholder of BPI.

Douglas Reed, M.D.
General Partner, Hatteras Venture Partners

Dr. Reed joined Hatteras Venture Partners as a General Partner in early 2007. Prior to Hatteras, Doug had 14 years of venture investing experience with two healthcare-focused funds, Vector Fund Management and SR One. He has been involved in venture investment transactions for over 30 healthcare and life science companies and currently serves on the boards of Viamet Pharmaceuticals and TetraLogic Pharmaceuticals and several private life sciences companies.

Robert Schotzinger, M.D., Ph.D.
President & CEO, Viamet Pharmaceuticals

Dr. Schotzinger brings over 20 years of research, development and management experience to Viamet Pharmaceuticals, where he has raised significant equity capital and moved Viamet from a seed-stage company to a clinical-stage company. Prior to joining Viamet, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company's lead drug candidate from phase 1 to phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his B.S. in Pharmacy from the Ohio State University. He subsequently earned his Ph.D. degree in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.

S. Edward Torres
Managing Director, Lilly Ventures

Mr. Torres is a managing director of Lilly Ventures Fund I LLC and brings over 20 years of pharmaceutical and venture capital experience to the Board. Ed currently sits on the boards of Viamet Pharmaceuticals, Receptos, several private life sciences companies and various non-profit institutions. Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses of Eli Lilly including operational finance, planning, M&A, business development and global marketing roles. Ed received a B.A. from Creighton University and a M.B.A. from the University of Michigan Business School, where he was a Consortium Fellow.

Phil Tracy
Venture Partner, Intersouth Partners

Mr. Tracy joined Intersouth Partners as a Venture Partner in 1997. Prior to that he spent twenty-one years in the pharmaceutical industry at Burroughs Wellcome Co. where he served as President and CEO from 1989 until its merger with Glaxo in 1995. Mr. Tracy serves on the Board of Directors of Intersouth Partners portfolio companies Viamet Pharmaceuticals, Inc. and Alimera Sciences, Inc., where he serves as Chairman. He is also Of Counsel to Raleigh law firm, Smith Anderson. Mr. Tracy received his B.A. from the University of Nebraska and his L.L.B from George Washington University.

Steve Weinstein
Managing Director, Novartis Venture Fund

Mr. Weinstein is a Managing Director of Novartis Venture Fund. Steve joined the Fund in 2006 and focuses on medical device and bio/pharma investments. He serves, or has served, on the boards of Viamet Pharmaceuticals, Ablation Frontiers (acquired by Medtronic), Advanced Animal Diagnostics, Autonomic Technologies Inc., Intersection Medical, Sonitus Medical and Visiogen (acquired by Abbott). Prior to Novartis Venture Fund, Steve was at Prism Venture Partners, where he focused on medical devices. Steve holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University's School of Engineering and Applied Science. He serves the Innovation Advisory Board of Partners Healthcare, and is a member of the Virginia GAP BioLife Fund Investment Committee, on the advisory board of the Wolverine Venture Fund (affiliated with the University of Michigan), and previously served on the Innovation Advisory Board of the Cleveland Clinic.

Kristopher Wood
Chief Investment Officer, Lurie Holdings

Kristopher is the chief investment officer at Lurie Holdings Inc. Prior to Lurie Holdings, he served as head of strategy and corporate development at World Color, a printing company. Previously, he was also an associate at MidOcean Partners, a private equity company. Kris also served as chief acquisitions officer for Glenayre Inc. and as managing director for mergers and acquisitions and venture capital at Vertis Holdings, Inc. Kris serves on the board of directors of several private companies. He received a B.S. from the Wharton School of the University of Pennsylvania.